Pacira BioSciences (NASDAQ:PCRX) Trading 4.7% Higher – What’s Next?

Pacira BioSciences, Inc. (NASDAQ:PCRX) shares traded up 4.7% during mid-day trading on Friday . The company traded as high as $24.26 and last traded at $24.43. 77,954 shares were traded during mid-day trading, a decline of 90% from the average session volume of 756,200 shares. The stock had previously closed at $23.33.

Wall Street Analysts Forecast Growth

PCRX has been the topic of a number of research analyst reports. Needham & Company LLC lifted their price target on Pacira BioSciences from $22.00 to $30.00 and gave the company a “buy” rating in a report on Monday, January 13th. Barclays lowered their target price on Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a research note on Tuesday, November 12th. Royal Bank of Canada reissued a “sector perform” rating and issued a $18.00 price target on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $39.00 price objective on shares of Pacira BioSciences in a research report on Wednesday, December 4th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $24.50.

Pacira BioSciences Stock Up 5.1 %

The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. The business’s fifty day moving average price is $19.34 and its two-hundred day moving average price is $17.54. The firm has a market cap of $1.13 billion, a P/E ratio of -12.08 and a beta of 0.76.

Institutional Trading of Pacira BioSciences

Several large investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. raised its stake in shares of Pacira BioSciences by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company’s stock valued at $184,000 after acquiring an additional 918 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Pacira BioSciences by 6.0% in the second quarter. The Manufacturers Life Insurance Company now owns 23,932 shares of the company’s stock valued at $685,000 after purchasing an additional 1,354 shares during the period. Profund Advisors LLC lifted its stake in shares of Pacira BioSciences by 26.2% in the second quarter. Profund Advisors LLC now owns 10,551 shares of the company’s stock worth $302,000 after buying an additional 2,190 shares during the last quarter. Nisa Investment Advisors LLC boosted its holdings in shares of Pacira BioSciences by 495.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock worth $62,000 after buying an additional 2,749 shares during the period. Finally, Mercer Global Advisors Inc. ADV grew its stake in Pacira BioSciences by 39.0% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 12,686 shares of the company’s stock valued at $363,000 after buying an additional 3,562 shares during the last quarter. Institutional investors own 99.73% of the company’s stock.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.